Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations

Cu/Zn superoxide dismutase (SOD1) reduction prolongs survival in SOD1‐transgenic animal models. Pyrimethamine produces dose‐dependent SOD1 reduction in cell culture systems. A previous phase 1 trial showed pyrimethamine lowers SOD1 levels in leukocytes in patients with SOD1 mutations. This study investigated whether pyrimethamine lowered SOD1 levels in the cerebrospinal fluid (CSF) in patients carrying SOD1 mutations linked to familial amyotrophic lateral sclerosis (fALS/SOD1).

• Publication year

  2017

• Venue

  Annals of Neurology

• Publication date

  2017-05-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/ana.24950PMID 28480639PMCID 5518287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Defining SOD1 ALS natural history to guide therapeutic clinical trial design

  2016influential reference
• Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.

  2014cited by this paper
• Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study

  2013influential reference
• State of play in amyotrophic lateral sclerosis genetics

  2013cited by this paper
• SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

  2013influential reference
• Amyotrophic lateral sclerosis.

  2012cited by this paper
• Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

  2011influential reference
• Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis

  2011cited by this paper
• ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival

  2011cited by this paper
• Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models.

  2010influential reference
• Novel Antibodies Reveal Inclusions Containing Non-Native SOD1 in Sporadic ALS Patients

  2010cited by this paper
• Correlates of quality of life in ALS: Lessons from the minocycline study

  2010cited by this paper
• Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS

  2010cited by this paper
• Superoxide dismutase in amyotrophic lateral sclerosis patients homozygous for the D90A mutation.

  2009cited by this paper
• Antisense oligonucleotide therapy for neurodegenerative disease.

  2006influential reference
• The value of database controls in pilot or futility studies in ALS

  2006cited by this paper
• SOD1 gene mutations in Italian patients with Sporadic Amyotrophic Lateral Sclerosis (ALS).

  2006cited by this paper
• Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates

  2006cited by this paper
• Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

  2005cited by this paper
• Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis.

  2004cited by this paper
• A cross sectional study on determinants of quality of life in ALS

  2004influential reference
• El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis

  2000cited by this paper
• Quality of life in ALS depends on factors other than strength and physical function

  2000influential reference
• The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

  1999cited by this paper
• CuZn‐Superoxide Dismutase, Extracellular Superoxide Dismutase, and Glutathione Peroxidase in Blood from Individuals Homozygous for Asp90Ala CuZn‐Superoxide Dismutase Mutation

  1998cited by this paper
• Normal Binding and Reactivity of Copper in Mutant Superoxide Dismutase Isolated from Amyotrophic Lateral Sclerosis Patients

  1997cited by this paper
• Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction.

  1995cited by this paper
• Transgenic-mouse model of amyotrophic lateral sclerosis.

  1994cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

  1993cited by this paper
• Binding of Pyrimethamine to Human Plasma Proteins and Erythrocytes

  1990cited by this paper
• Spectrophotometric study of spontaneous disproportionation of superoxide anion radical and sensitive direct assay for superoxide dismutase.

  1976cited by this paper

• Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention.

  2025cites this paper
• SOD1, A Crucial Protein for Neural Biochemistry: Dysfunction and Risk of Amyotrophic Lateral Sclerosis

  2025cites this paper
• RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice.

  2025cites this paper
• Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects

  2025cites this paper
• Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis

  2025cites this paper
• Variability in SOD1-associated amyotrophic lateral sclerosis: geographic patterns, clinical heterogeneity, molecular alterations, and therapeutic implications

  2024cites this paper
• Specific analysis of SOD1 enzymatic activity in CSF from ALS patients with and without SOD1 mutations.

  2024cites this paper
• RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice

  2024cites this paper
• Current potential pathogenic mechanisms of copper-zinc superoxide dismutase 1 (SOD1) in amyotrophic lateral sclerosis

  2024cites this paper
• Nucleocytoplasmic transport at the crossroads of proteostasis, neurodegeneration and neuroprotection

  2023cites this paper
• Biomarkers in amyotrophic lateral sclerosis: current status and future prospects

  2023cites this paper
• Analysis of proteome-wide degradation dynamics in ALS SOD1 iPSC-derived patient neurons reveals disrupted VCP homeostasis

  2023cites this paper
• Intercellular transmission of pathogenic proteins in ALS: Exploring the pathogenic wave.

  2023cites this paper
• Respiratory onset of amyotrophic lateral sclerosis in a pregnant woman with a novel SOD1 mutation

  2022cites this paper
• A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis

  2022cites this paper
• Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle

  2022cites this paper
• Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis

  2022cites this paper
• The Advent of Omics Sciences in Clinical Trials of Motor Neuron Diseases

  2022influential citation
• Treatment of hereditary amyotrophic lateral sclerosis.

  2022cites this paper
• Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia

  2022cites this paper
• Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders

  2021cites this paper
• Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics

  2021cites this paper
• Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New

  2021cites this paper
• The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future

  2020cites this paper
• SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential

  2020cites this paper
• Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis?

  2020cites this paper
• Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic

  2020cites this paper
• Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases

  2019cites this paper
• Better survival in female SOD1-mutant patients with ALS: a study of SOD1-related natural history

  2019cites this paper
• Biomarkers in Motor Neuron Disease: A State of the Art Review

  2019cites this paper
• High-throughput drug screens for amyotrophic lateral sclerosis drug discovery

  2018cites this paper
• Pathological hydrogen peroxide triggers the fibrillization of wild-type SOD1 via sulfenic acid modification of Cys-111

  2018cites this paper
• Comprehensive analysis of the mutation spectrum in 301 German ALS families

  2018cites this paper
• A Proposed Mechanism for Neurodegeneration in Movement Disorders Characterized by Metal Dyshomeostasis and Oxidative Stress.

  2018cites this paper